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Leukemia remains the most common diagnosis in pediatric oncology and, despite dra-
matic progress in upfront therapy, is also the most common cause of cancer-related death
in children. Much of the initial improvement in outcomes for acute lymphoblastic leukemia
(ALL) was due to identification of cytotoxic agents that are active against leukemia followed
by the recognition that combination of these cytotoxic agents and prolonged therapy are
essential for cure. Recent data demonstrating lack of progress in patients for whom stan-
dard chemotherapy fails suggests that the ability to improve outcome for these children
will not be dramatically impacted through more intensive or newer cytotoxic agents.Thus,
much of the recent research focus has been in the area of improving our understanding of
the genetics and the biology of leukemia. Although in vitro studies remain critical, given the
complexity of a living system and the increasing recognition of the contribution of leukemia
extrinsic factors such as the bone marrow microenvironment, in vivo models have provided
important insights.The murine systems that are used can be broadly categorized into syn-
geneic models in which a murine leukemia can be studied in immunologically intact hosts
and xenograft models where human leukemias are studied in highly immunocompromised
murine hosts. Both of these systems have limitations such that neither can be used exclu-
sively to study all aspects of leukemia biology and therapeutics for humans. This review
will describe the various ALL model systems that have been developed as well as discuss
the advantages and disadvantages inherent to these systems that make each particularly
suitable for specific types of studies.
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SYNGENEIC MOUSE MODELS OF ALL
The identification of genetic changes in acute lymphoblastic
leukemia (ALL) such as chromosomal translocations, gene ampli-
fication, and gene inactivation/deletion has revolutionized our
understanding of the potential drivers of leukemogenesis. These
have served as a basis for development of murine models that
recapitulate human ALL. Genetic modification of ALL associated
genes in primary cells with subsequent transplantation into mice,
generation of transgenic mice that modify ALL associated genes
in the lymphoid compartment, and chemical carcinogen induced
mouse models have all been employed to try to model human
pediatric ALL. In this section, we will focus on syngeneic mod-
els that have been shown to develop ALL that employ the first
two methodologies as they utilize reverse genetics, which is more
relevant to what occurs in human ALL.
B CELL ALL MODELS
ETV6-RUNX1 (TEL-AML1)
The t(12;21)(p13;q22) chromosomal translocation encodes a
novel fusion protein ETS variant 6 (ETV6)-runt-related transcrip-
tion factor 1 (RUNX1) and is the most common rearrangement
that occurs in ~25% of cases of pediatric B cell ALL (1). The
ETV6-RUNX1 fusion protein consists of the basic helix loop
helix (bHLH) domain of ETV6 combined with the transactiva-
tion domains of RUNX1. ETV6 belongs to the ETS family of
transcription factors and has been found to have at least 20 differ-
ent gene fusion partners and is also found to have other genetic
alterations including deletions, point mutations, and promoter
alterations in various leukemias (2). RUNX1 binds to DNA as
part of the RUNX1/CBFβ transcription factor complex and the
RUNX1 gene locus is commonly amplified in childhood ALL
(3). Clinically, ETV6-RUNX1 expression is correlated with good
prognosis (4).
Different groups have taken either bone marrow (BM) or fetal
liver cells from mice and retrovirally transduced these cells to
express ETV6-RUNX1 protein in an attempt to model human
ALL. In three models, no incidence of leukemia was observed
but increased numbers of precursor B cells were found with
deficiencies of more mature B cells (5–7). In the BM models,
increased ckit positive multi-potential progenitors were found
with increased self-renewal potential of cells that expressed ETV6-
RUNX1. In a fourth model of transduced BM, 2 of 9 mice that
received translocation expressing BM developed ALL compared
to 0 out of 20 control mice (8). Of the mice that had leukemia, one
developed a T lineage ALL while the other developed a precursor B
ALL (B ALL will be used to denote precursor B ALL throughout the
rest of the review and a more mature B cell disease will be noted
as such). In this same report, BM from p16INK4a/p19ARF mice
were also transduced with ETV6-RUNX1 and six of eight mice
developed leukemia while no control mice developed leukemia.
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Transgenic mice have also been employed to try to model ETV6-
RUNX1 leukemias. The first study utilized the immunoglobulin
heavy chain enhancer (Eµ) to drive expression of ETV6-RUNX1 in
mice, however no leukemia was observed (9). This result was cor-
roborated in subsequent reports where no leukemia was observed
despite the use of differing gene promoters to express the translo-
cation. Pre-leukemic changes in the BM were shown in a second
transgenic model as pre-pro-B cell numbers were increased in
mice (10). Based on three other reports, it appears likely that a
second genetic event is necessary for the development of leukemia
as co-expression of other genes and mutations induced by irradi-
ation or carcinogens increased the incidence of leukemia (11–13).
These data are supported by the clinical observation that ETV6-
RUNX1 has been detected at birth prior to the development of
leukemia (14).
E2A-PBX1
The fusion protein consisting of the N-terminal transactivation
domain of E2A protein and C terminal DNA binding homeobox
domain of pre-B cell leukemia homeobox (PBX1) is expressed
from the t(1;19)(q23;p13) and is detectable in 6% of childhood B
ALL (15). E2A (transcription factor 3, TCF3) is a bHLH protein
that codes for alternatively spliced transcripts for E12 and E47 pro-
teins found to be required for B cell development (16). PBX1 was
found to be necessary for lymphoid precursor development (17).
Two groups have studied which domains are required for E2A-
PBX1 transforming activity and found that the homeodomain of
PBX1 which is responsible for binding to DNA is not necessary
for oncogenesis (18, 19). However, the homeobox domain was
important for blocking differentiation of myeloblasts (18). It was
later found that a HOX cooperativity motif in PBX1 was needed
to mediate transformation with E2A-PBX1 (20).
Initial attempts at modeling E2A-PBX1 driven leukemias were
successful at causing myeloid leukemias and lymphomas, but not
lymphoblastic leukemias. BM transduced with E2A-PBX1 from
BALB/C mice led to the formation of acute myelogenous leukemia
with an increase in immature blast cells in the BM (21). FVB trans-
genic mice in which E2A-PBX1 expression was driven with IgH
V-gene promoter fused to Eµ died within 5 months of age of T cell
lymphomas (22). These mice showed reduced numbers of T and B
cell progenitors that were at 20% of normal levels. Though impor-
tant to study the oncogenic potential of E2A-PBX1, these models
did not reproduce the association of E2A-PBX1 expression seen in
B ALL so the relevance of these model systems to human disease
is not clear.
A later model succeeded in replicating E2A-PBX1 B ALL in mice
(23). In this transgenic mouse, E2A-PBX1 is expressed under con-
trol of lymphoid specific Lck upstream sequence, Eµ enhancer,
and TCR Vβ promoter. Interestingly, mice expressing the trans-
gene that died at an earlier age were prone to developing T ALL
in contrast to mice who developed leukemia at later timepoints,
which succumbed to B ALL or mixed lineage ALL. E2A-PBX1
transgenic mice were crossed into a CD3ε−/− background, which
led to 40% of mice acquiring B ALL. These mice had a long
latency time before symptoms of disease were observed and this
latency was reduced when combined with Hox gene overexpres-
sion by viral insertional mutagenesis. In addition to Hox genes,
Pim1, Notch1, and downregulation of INK4A-ARF by Bmi-1 have
also been shown to cooperate with E2A-PBX1 in oncogenesis sug-
gesting the importance of secondary hits in the development of
E2A-PBX1 driven leukemias (24–26).
E2A-HLF t(17;19)(q22;p13)
E2A-hepatic leukemia factor (HLF) protein is the result of
t(17;19)(q22;p13) translocation most commonly found in ado-
lescents as a high risk pro-B cell ALL, yet is a rare event (27).
Similar to the E2A-PBX gene fusion, the N-terminal transacti-
vation domains of E2A are joined to the basic leucine zipper
dimerization domain of HLF. HLF is a member of the proline
and acidic amino acid-rich basic leucine zipper (PAR bZip) tran-
scription factor family and mice deficient in this protein develop
without any cancer pathology (28). Both transactivation domains
of E2A and the basic leucine zipper dimerization domain of HLF
were required for transformation of NIH3T3 mouse fibroblasts
(29). The transforming ability may in part be due to upregulation
of LIM domain only 2 (LMO2) (30).
Two transgenic mouse models of E2A-HLF were developed
with slightly different results. The first model used the Eµ enhancer
with the SV40 promoter to drive expression of the translocation
(31). In this report, they described changes in the precursor T cell
populations in the thymus and spleen with mature splenic B cells
expressing low levels of E2A-HLF. Sixty percent of mice became
sick with lymphomas, 90% of which were derived from a T cell
lineage, and the remaining 10% of B cell origin. A second model
also used the Eµ enhancer with its corresponding promoter to
express E2A-HLF (32). An increase in T cell apoptosis in the thy-
mus and a block in the maturation of B cells in the spleen was
observed. These mice showed incomplete penetrance with 5 of 26
mice developing T ALL.
A later study used BM transduction to study the leukemogenic
inducing potential of E2A-HLF (33). BM was transduced with
a murine stem cell retrovirus to express transgenes and grown
in vitro on irradiated AC-6.21 stromal cells before transplanta-
tion. These transduced cells without additional mutations did
not induce leukemia in non-irradiated hosts. However, BM cells
that were transduced to express E2A-HLF with Bcl-2 and trans-
planted immediately into lethally irradiated hosts did develop B
ALL, which is similar to the disease seen in human B ALL.
BCR-ABL
Breakpoint cluster region (BCR)-ABL is the protein product
caused by the t(9;22)(q34;q11) translocation (also known as the
Philadelphia chromosome) is most commonly found in CML, but
also accounts for 20–40% of adult B ALL and 3–5% of childhood
B ALL cases (34, 35). Expression of the translocation product is
controlled by the BCR promoter, which is ubiquitously expressed
throughout the body (36).BCR null mice show alterations in activ-
ity of neutrophils (37) while ABL1 knockout mice exhibit wasting
of the spleen and thymus as well as significant loss of B and T cell
numbers (38, 39). Two versions of the fusion protein associated
with ALL are generated from different breakpoints leading to a
210-kDa protein (p210) and a 190-kDa protein (p190). The p210
isoform is detectable in 33% of adult Philadelphia chromosome
positive (Ph+) ALL with the rest of cases expressing the shorter
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isoform. The p190 accounts for 90% of Ph+ ALL cases in child-
hood ALL. The BCR-ABL fusion protein is a constitutively active
non-receptor tyrosine kinase due to removal of the domains of
ABL1 that normally keep ABL1 in an inactive closed conforma-
tion (40) and this deregulation leads to transformation. There have
been many reports to study the function of the BCR-ABL translo-
cation in many leukemia models, however this section will focus
on the work that pertains to studies of ALL in BCR-ABL model
systems.
Early attempts to model ALL in transgenic mice used the
metallothionein-1 promoter, which has broad tissue expression
in the mouse, to express p190 BCR-ABL (41). This promoter was
chosen as attempts to use the BCR promoter to drive expression of
BCR-ABL, as occurs in human leukemia, led to embryonic lethal-
ity of mice. Of ten mice examined, two mice developed AML
while six mice were diagnosed with B ALL. Though Heisterkamp
et al. showed embryonic lethality using a BCR promoter, another
report showed that a p190 BCR-ABL knock-in model, which has
expression of p190 from the endogenousBCR gene locus, develops
B ALL with high frequency in chimeric animals (42). In con-
trast, expression of p210 from the endogenous BCR locus does
not result in neoplastic transformation of hematopoietic cells to
form leukemia (43). Further work from the Heisterkamp group
explored what happens when the p210 isoform of BCR-ABL is
expressed using the metallothionein-1 promoter (44). p210 trans-
genic mice became sick from B, T, and myeloid leukemia with a
long latency period while mice that expressed p190 only devel-
oped B ALL with a rapid disease course. A second (Honda et al.)
publication also described a p210 BCR-ABL model driven by the
same metallothionein-1 promoter (45). Interestingly, in this model
two of six mice developed leukemia committed to the T cell lin-
eage. The reasons underlying the difference in the spectrum of
diseases seen in these p210 models are not clear, though differ-
ences in either strains of mice used or differences in promoter
sequences used may contribute. Honda et al. created another
BCR-ABL transgenic mouse that used the mouse Tec promoter
to regulate p210 BCR-ABL expression (46). Tec is a cytoplasmic
protein tyrosine kinase that is expressed in hematopoietic progen-
itor cells. Two of five founder mice developed ALL and the progeny
of one of these mice developed CML at 1 year of age with some
mice showing hallmarks of blast crisis in the lung. Another group
took advantage of advances in tetracycline transactivator (tTA)
proteins to regulate gene expression of p210 BCR-ABL (47). They
used a “tet-off” system with the mouse mammary tumor virus
long terminal repeat (MMTV-LTR) promoter, which controlled
tTA protein. This allowed expression of p210 in the absence of
tetracycline in the water of mice and repression of expression when
mice were given tetracycline. In this model, mice developed B ALL
and initiation and maintenance of ALL was dependent on p210
expression.
Bone marrow transduction studies have shown that BCR-
ABL is capable of inducing multiple types of leukemia. Although
the initial intention of this study was to model CML, expres-
sion of p210 via a myeloproliferative sarcoma virus (MPSV)
in BM cells from BALB/c led not only to CML, but B and T
ALL and macrophage derived tumor in 13 of 30 mice studied
(48). A follow-up report using the same p210 BCR-ABL protein
(b3a2) in BALB/c BM transduction/transplant studies, compared
another p210 BCR-ABL protein (b2a2), resulting from an alterna-
tive breakpoint, when driven by a murine stem cell virus (MSCV)
U3 promoter found that both gave rise to B ALL without any
evidence of myeloid leukemia (49). Yet another group utilized a
MPSV system to express p210 BCR-ABL in mouse BM and also
observed a broad range of diseases in two different mouse strains
(50). In both DBA/2 and C57BL/6 mice, macrophage and ery-
throid derived tumors were found, while in lymphoid derived
tissues DBA/2 mice developed B cell lineage lymphomas while
C57BL/6 mice developed T lineage lymphomas. In contrast to
the previous report classical CML was not observed in either of
these strains of mice. Another BALB/c BM transduction model
was used with a Moloney murine leukemia virus (Mo-MuLV) to
express p210 BCR-ABL with half of the animals developing CML
like disease while the other half developed pre-B cell lymphomas
(51). Another study using BALB/c mice used BM transduced with
MSCV controlling expression of p190, p210, or p230 BCR-ABL,
which is commonly associated with chronic neutrophilic leukemia
(52). When BM from mice pre-treated with 5-fluoro uracil (5-
FU), which enriches multi-potential myeloid cells in the BM, were
transplanted to recipient mice all three isoforms of BCR-ABL gave
rise to CML like disease in all mice with similar latency for develop-
ment of disease. When the BM without 5-FU treatment was used
for transduction and transplant, mice developed diseases of var-
ious lineages, which included not only CML like but also B ALL
and macrophage lineage disease. The p190 isoform in the latter
experiment showed more aggressiveness as these mice acquired
disease at earlier timepoints with an increased incidence of B
ALL. BM185 cells are another model system in which BALB/c BM
is grown in early B cell progenitor Whitlock Witte cultures and
transduced with p190 BCR-ABL. These cells when intravenously
transplanted into mice developed B ALL with as little as 1000 cells
in 3 weeks with 100% penetrance. (53). These findings underscore
the complexity of modeling human disease as expression of the
same cancer associated protein can have vastly different effects in
mice and may be due to strain differences or use of alternative viral
vectors. In addition, the cell of origin is another potential factor
in disease variability highlighted by the fact that transplantation
of a late onset CML like disease driven by p210 BCR-ABL in a BM
transduction/transplant model led to not only myeloid disease,
but also B and T ALL (54).
MLL FUSIONS
The mixed lineage leukemia (MLL) gene is most frequently found
rearranged in infant ALL accounting for two-thirds of infant ALL
cases and less frequently in AML and confers a worse prognosis
(55, 56). There have been 121 rearrangements of MLL identi-
fied with 79 translocation partner genes characterized molecularly
(57). The seven most common rearrangements involve AF4, AF9,
ENL, AF10, ELL, AF6, or derive from partial tandem duplications
of the MLL gene (MLL-PTD). The MLL-PTD are rare in acute
lymphoblastic leukemia (58) and have not been modeled thus far
and will not be covered in this review. Despite the rare instances
of ALL in these models, we will highlight the work that has been
done in mice with these common rearrangements that have been
identified in ALL.
www.frontiersin.org May 2014 | Volume 4 | Article 95 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jacoby et al. Murine models of acute leukemia
MLL-AF4
MLL-AF4/AFF1 is the product of t(4;11)(q21;q23) and account
for about 50% of cases of MLL rearrangement. Mouse models
have used various approaches to express the MLL-AF4 protein. A
standard transgenic mouse using pronuclear injection of MSCV
MLL-AF4 had B cell neoplasms found in the spleen, liver, lung, and
blood after a long period of latency (59). Knock-in mouse mod-
els were also generated by using the MLL gene locus to express
MLL-AF4. The first model used traditional gene targeting to fuse
human AF4 to exon 7 of mouse MLL (60). These mice devel-
oped lymphoid and myeloid hyperplasia with the most common
malignancies of B cell lineage at 22 months of age. The second
knock-in mouse was an inverter mouse that utilized a Cre/Lox
system to cause a recombination event to happen after Cre expres-
sion that would cause MLL-AF4 to be expressed instead of normal
MLL (61). These mice developed more mature B cell neoplasms
as opposed to B ALL from which the cDNA for AF4 was originally
isolated to generate the mice. The last model made use of a Lox
Stop Lox cassette to halt transcription of AF4 in the MLL locus
prior to Cre recombination (62). MLL-AF4 was only expressed in
cells in which Cre recombination occurred and led to ALL and
AML in mice.
Bone marrow transduction has also been used to model MLL-
AF4 leukemogenesis. In the Lox Stop Lox model, BM transduced
with a transiently expressed Cre led to ALL, AML and MLL after
transplant back into mice (62). In a separate report using MSCV
MLL-AF4 transduced BM, leukemogenesis required expression
of the normal MLL gene (63). Another study found that MLL-
AF4 and its reciprocal translocation AF4-MLL were both able
to cause ALL of all subtypes (B, T, mixed lineage) in mice that
were transplanted with BM that expressed each alone or when
co-expressed (64).
MLL-AF9
The t(9;11)(p22;q23) chromosomal rearrangement produces the
MLL-AF9/MLLT3 leukemia associated protein. Two mouse mod-
els have been created to model MLL-AF9 leukemia. MLL-AF9
was targeted to the MLL locus in mice and expressed using
native MLL gene regulatory elements (65). These mice only devel-
oped AML. In the second model, the investigators took a novel
approach using Cre recombination where single LoxP sites were
introduced into the endogenous MLL and AF9 genes to create
Cre mediated interchromosomal recombination of MLL and AF9
(66). Chimeric mice generated using this strategy developed acute
leukemias and in mice analyzed and was classified as AML. BM
transduction/transplantation (tp) model AML has been recently
reported (67). MLL-AF9 has also been transduced in granulocyte
macrophage progenitors to produce AML (68).
MLL-ENL
MLL-ENL is the product of the t(11;19) (q23;p13.3) translo-
cation. The only reported interchromosomal gene recombined
mouse model of MLL-ENL developed myeloid leukemias (69).
BM transduction models have been made but not all studies have
involved transplant into mice. MSCV MLL-ENL was introduced
into early hematopoietic progenitors and transplanted into mice,
which led to myeloid leukemias (70). In a separate study, MSCV
MLL-ENL transduced BM grown in ex vivo conditions favoring
lymphopoiesis without a stromal feeder layer induced a contin-
uously growing cell population (71). The proliferating cells were
initially B220+CD19+, but after continual growth a B220+CD19−
population dominated the culture. The B220+CD19− cells could
induce splenomegaly and infiltrated the thymus of mice and
despite being morphologically myeloid, they retained B220 posi-
tivity showing a mixed lineage phenotype. Later BM transduction
models used conditional MLL-ENL. A mutated estrogen receptor
fusion protein of MLL-ENL was used, but not introduced into
animals so the resultant disease was not reported (72). A tetracy-
cline regulatable MLL-ENL when used to transduce BM was able
to induce AML and expression of MLL-ENL protein was required
for leukemic growth even in leukemias that acquired secondary
mutations (73).
MLL-AF10
MLL-AF10 is derived from the rearrangement t(10;11)(p13–
15;q14–21). Only BM transduction studies have been done using
this gene fusion. Two studies use the same MSCV based BM trans-
duction withMLL-AF10 and both models develop myeloid lineage
disease (74, 75). An additional model studied the cooperativity of
MLL-AF10 with the activating mutation Kras G12C (76).
MLL-ELL
The only published study of MLL-ELL gene fusions utilized a
MSCV based BM transduction strategy, where C terminal domain
of ELL was shown to be required for transformation of myeloid
progenitor cells. In this study, there was no data shown for
transplantation of these transduced cells into mice but MLL-
ELL expression caused immortalization of myeloid progenitors
in vitro (77).
MLL-AF6
The only MLL-AF6 model of leukemia used BM transduction to
demonstrate the requirement of histone methyltransferase Dot1l
for MLL-AF6 induced leukemogenesis (78).
PAX 5 DELETIONS
Somatic mutations and deletions of PAX5 have been found in
about 30% of pediatric B ALL samples (79). To date, only haploin-
sufficiency of PAX5 was shown to be important for induction of
leukemia in an activated STAT5 B ALL mouse model (80).
IGH-Myc
Myc translocations occur in about 5% of both adult and child-
hood ALL (81). Transgenic mice that express Myc under control of
IGH enhancers showed B cell lymphomas with leukemic involve-
ment at later timepoints (82, 83). Knock-in of Myc into the
native IGH locus induced B cell neoplasms (84). BM transduc-
tion studies using p53 null BM transduced with Myc led to B cell
lymphomas (85).
T CELL ALL
NOTCH1 ACTIVATION
NOTCH1 is a type I transmembrane receptor that is involved
in signal transduction and is the only NOTCH gene involved
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in T ALL (86). Activation of the NOTCH1 pathway is found in
over 50% of T ALL cases (87). In concordance with this clinical
data, NOTCH1 mutation has been identified in two transgenic
mouse T ALL models induced by KRas G12D (88, 89). No T
ALL transgenic models have been shown to be solely driven by
NOTCH1 mutations, but BM transduction/transplantation stud-
ies have shown that NOTCH1 activating mutants can drive T
ALL formation. A L1601P∆P mutant, which has a L1601P and
frameshift mutation in the PEST domain of NOTCH1 was shown
to inefficiently induce T ALL in mice after transduction and trans-
plantation into mice (90). A separate NOTCH1 mutant (ICN1)
which consists of the transmembrane and intracellular domain of
NOTCH1 was able to induce T ALL in BM cells transduced with
ICN1 after transplant into mice (91). Transgenic mice express-
ing ICN1 in T cell progenitors have also been shown to develop
T ALL (92).
INACTIVATION SCFFBW7
FBW7 is subunit of the SCF-type E3 ubiquitin ligases.FBW7 muta-
tions are found in many human cancers such as T ALL, which
corroborates its role as a tumor suppressor (93). Conditional inac-
tivation of FBW7 in T cell lineage cells in mice caused thymic
hyperplasia likely due to Myc accumulation (94).
TAL1 AND LYL1 MUTATIONS
TAL1 is a class II bHLH transcription factor that is a master regula-
tor for commitment to the hematopoietic lineage.TAL1mutations
or translocations are found in about 25% of childhood T ALL (95,
96). Lck promoter driven TAL1 transgenic mice also develop lym-
phomas of a predominantly mixed T and B cell phenotype (97).
Transgenic mice where a TAL1 DNA binding mutant is expressed
still develop T cell leukemia/lymphoma (98). bHLH proteins are
commonly found to interact with other bHLH proteins as het-
erodimers to regulate gene expression and a potential hypothesis
for the role of TAL1 in T ALL is that overexpression of TAL1 and
its mutants disrupt the normal gene program by interacting with
other transcription factors that regulate T cell development such
as E2A proteins (98).
LYL1 is also a class II bHLH transcription factor that het-
erodimerizes with class I bHLH transcription factors. Transgenic
mice that express LYL1 developed T cell lymphomas positive for
both CD4 and CD8 and mature B cell lymphomas (99). LYL1 is
also proposed to alter transcription through its interaction with
other transcription factors such as E2A (99).
LIM DOMAIN ONLY 2
LIM domain only 2 is a cysteine rich protein that cooperates with
other nuclear proteins to regulate gene transcription. Three trans-
genic models of LMO2 have been studied in relation to T ALL
and differ in choice of promoter to drive expression of LMO2.
Metallothionein-1 promoter led to 10% of LMO2 transgenic mice
developing CD4/CD8 double positive, single positive, and double
negative T cell neoplasms (100). Higher penetrance was seen in
75% of mice that expressed LMO2 under control of the CD2 pro-
moter (101). A third mouse reported used Lck promoter to express
LMO2 and showed cooperation with TAL1, a known binding
partner to LMO2, to induce T ALL (102).
CALM-AF10
The translocation t(10;11)(p13;q14–21) creates the CALM-AF10
fusion protein. They are most commonly found in TCRγδ express-
ing T ALL. Vav driven CALM-AF10 in a transgenic mouse model
led to mixed lineage ALL (103). BM transduced with MSCV dri-
ven CALM-AF10 and transplanted into mice led to leukemias
that expressed predominantly myeloid markers Mac1 and Gr1
and more rarely B cell marker B220 alone or co-expressed with
Mac1 and Gr1 (104). A recent study also showed that CALM-AF10
transformation is dependent on the histone methyltransferase
Dot1l (105).
SUMMARY OF SYNGENEIC MOUSE MODELS OF ALL
There has been significant progress made in trying to model ALL
in mice. The number of exogenous and endogenous promoters
to control expression of leukemia associated genes and mutations
has grown significantly and their tissue expression has been well
characterized. Advances in conditional mouse technology have
also been rapidly incorporated into various models with inducible
models providing exquisite control of transgene expression in cell
lineages. Through the use of BM transduction, a more rapid dis-
ease course is possible as secondary mutations can be introduced
that cooperate with primary mutations. This is important because
in the majority of ALL models long periods of latency are seen
with expression of single leukemia associated aberrations in mice,
which make study of these lesions difficult and time consuming.
The development of these ALL models (summarized in Table 1)
has contributed greatly to our understanding not only of pathways
that underlie leukemogenesis, but also helps us identify potential
therapeutic targets in these pathways.
Despite the promise in these models, there seems to be some dis-
crepancies in the disease observed driven by these ALL associated
genetic events. In trying to study ALL, expression of ALL associated
genes/mutations/translocations has led to AML in a significant
number of instances. This could be due to promoter choice, cell of
origin or cross species protein expression. Various promoters have
been used to try to express leukemia associated alterations in genes
and promoter choice affects the cells that express those gene prod-
ucts. This would explain why the same leukemia factor expressed
under control of alternative gene promoters leads to different dis-
eases in mice than in humans. Additionally, there may be complica-
tions that arise in expressing human leukemia associated proteins
in a mouse. Protein–protein interactions that exist in humans may
be absent or different in mice and therefore proper reproduction
of human disease in mice may become more difficult.
There are advantages for using syngeneic models of ALL. The
contribution of the microenvironment to the development of
many cancers is an important topic of study in carcinogenesis.
Cytokines, growth factors, and cell–cell interactions provided by
the local tumor microenvironment influence how cancers initiate
and develop. Syngeneic models of ALL can be utilized to study
the tumor microenvironment and its contribution to leukemo-
genesis. There are factors that contribute to leukemogenesis that
do not signal across species and therefore would be important to
study in a single species model. For example, the role of thymic
stromal lymphopoietin receptor overexpression (TSLPR/CRLF2)
in B ALL is being studied. TSLP, the ligand for TSLPR, does not
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Table 1 | Syngeneic mouse models of ALL.
Gene alteration Murine model Diseases observed Secondary mutations Reference
ETV6-RUNX1;
t(12;21)(p13;q22)
TM B ALL Cdkn2a−/−, chemical carcinogen induced,
insertional mutagenesis
(11–13)
BM T ALL, B ALL Not reported (8)
E2A-PBX1;
t(1;19)(q23;p13)
TM T, B, and mixed lineage ALL Pim1, Notch1, and downregulation of
INK4A-ARF by Bmi-1
(23–26)
E2A-HLF ;
t(17;19)(q22;p13)
TM T ALL Not reported (32)
BM B ALL Bcl-2 (33)
BCR-ABL;
t(9;22)(q34;q11)
TM AML, T ALL, B ALL Not reported (41, 42, 44–47)
BM CML, T ALL, B ALL, macrophage
derived tumor
Not reported (48, 49, 52–54)
MLL-AF4;
t(4;11)(q21;q23)
TM B lymphoma, B ALL, AML Not reported [60; 62]
BM B ALL, mixed lineage ALL, AML Not reported (62, 64)
MLL-ENL;
t(9;11)(p22;q23)
BM B ALL, mixed lineage ALL Not reported (71)
Pax5 haploinsufficiency TM B ALL STAT5 activation (80)
IGH-Myc TM B lymphoma, B ALL Not reported (82, 83)
NOTCH1 activation TM T ALL KRas G12D (88, 89, 92)
BM T ALL Not reported (90, 91)
TAL1 mutations TM T lymphoma, T ALL Not reported (98)
LMO2 TM T lymphoma, T ALL Not reported (100–102)
TM, transgenic mouse model; BM, bone marrow transduction/transplantation model; T ALL, T cell acute lymphoblastic leukemia; B ALL, B cell acute lymphoblastic
leukemia.
signal cross species so study of TSLPR overexpressing leukemia
must be pursued in a single species model. Syngeneic models of
TSLPR overexpressing B ALL would allow study of disease course
in the presence of ligand at physiologic doses that is not pos-
sible in a xenograft model. Expression of human TSLP in mice
would be required to study human TSLPR overexpressing B ALL
in xenograft model systems where mimicking physiologic levels of
the ligand could be problematic.
XENOGRAFT MODELS: DEVELOPMENT OF THE HUMAN
ALL-BEARING MOUSE
The pursuit of an animal model that would provide in vivo insights
of direct relevance to human ALL has been undertaken by many
groups using multiple types of immunodeficient mice to allow
engraftment of human cells. The first candidate was the athymic
nude mouse, developed in the late 1960s. Lack of T cells allowed
engraftment of some human tissues and tumors, but intact NK
cells and B cells prevented engraftment of human hematopoi-
etic cells. Still, by conditioning mice with radiation, initial studies
demonstrated some ability for leukemia cells to engraft (106–108).
Nonetheless, engraftment of cells administered intravenously was
extremely difficult. Thus, in these models, recipients were inoc-
ulated with leukemia cell lines in the intradermal, subcutaneous
or intraperitoneal compartments, and at times required an addi-
tion of irradiated cells from a fibrosarcoma cell line in order to
engraft (107). The results were ascites (106) or solid masses (108)
of leukemia origin, which allowed studying of new drugs and ther-
apeutic approaches. However, the leukemia lacked its “normal”
BM niche and natural course in extramedullary organs. Thus, the
study of homing, engraftment, persistence, course, and therapeu-
tic approaches in the native leukemia niche was impossible in this
model.
Introduction of the severe combined immunodeficiency
(SCID) mouse on a CB17 background (109), was a major advance
in the field, allowing marrow engraftment of human hematopoi-
etic cells [reviewed by Shultz (110)]. These mice have a deletion
in Prkdc, an essential protein involved in DNA repair following
VDJ recombination in T and B cells. Hence, these mice lack adap-
tive immune cells, but retain NK cells as well as innate immunity;
therefore, these models often required conditioning with sublethal
irradiation to engraft human leukemia (111), though some groups
overcame this need by repeated in vivo transfers of the leukemia
cell line. An important breakthrough was the use of SCID mice
to engraft patient derived primary leukemia cells following an IV
injection (112). This resulted in engraftment and proliferation
of the leukemia in vivo, with infiltration of the spleen, liver, kid-
ney, lung, central nervous system, (112) lymph nodes and ovaries
(113), thus imitating extramedullary involvement. Also, compared
to nude mice, SCID mice engrafted leukemia following a lower
inoculation dose (114).
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Several attempts were made to genetically manipulate the SCID
mouse to increase the engraftment ability of the SCID mouse. The
SCID-beige mouse was developed by adding a mutation in the
lysosome trafficking regulator (Lyst ) to the Prkdcscid mutation, on
a Balb/c or CB57/BL/6J background. This resulted in lack of T and
B cells as well as neutropenia and reduced NK function; moreover,
these strains avoided the late immune-reconstitution seen in SCID
mice (115). This model can engraft leukemia and has been used
by a number of groups in leukemia research (116).
The NOD-SCID mouse was generated by crossing the SCID
mouse (Prkdcscid) to the non-obese diabetic (NOD/Lt) mouse
background, resulting in reduced NK function as well as impaired
innate immunity derived from the NOD mutation in a diabetes-
free strain (110,117). This mouse showed increased rate of engraft-
ment of human hematopoietic cells in general, including ALL cell
lines and patient samples (118, 119). Moreover, impaired NK func-
tion reduced the need for conditioning with radiation prior to
leukemia administration, though conditioning with irradiation
was still used by investigators (120, 121). This was of impor-
tance, since these mice have a tendency to develop spontaneous
thymic lymphoma, and have generally a short life span [median
survival of 257 days (117)]. Human leukemia seemed to have stable
properties when passed to an NOD-SCID mouse, with stable anti-
genic markers, T- or B-cell receptor rearrangements, karyotype,
as well as a stable rate of engraftment in subsequent passes of the
leukemia (121, 122).
Crossing the common-gamma-chain (interleukin 2 recep-
tor gamma) knockout to the NOD-SCID mouse generated the
NOD/SCID/γC− (or NSG mouse), with multiple defects in both
the innate and the adaptive immune system. Lack of NK cells
omitted the need for irradiation prior to leukemia administra-
tion. NSG mice have superior engraftment of ALL cells in terms of
time to engraftment (shorted by ~2 weeks compared with NOD-
SCID mice), ability to detect blasts in the peripheral blood, and
total number of cells required to engraft (123, 124). NSG mice
can even be engrafted with as little as 1–100 cells derived from
patients with poor-prognosis ALL (125). Again, as in the NOD-
SCID model, patient derived B or T -lineage ALL engrafted in
NSG mice have a stable phenotype and transcriptome, even after
a several passes in vivo (126). The relative simplicity of engrafting
human leukemia in these mice made the NSG model excellent for
leukemia research.
In summary, the evolution of the immunocompromised
mouse, with its ability to engraft human hematopoietic cells, pro-
vided in vivo models for studying human ALL. Nevertheless, there
are some significant drawbacks in using these mice. Since they have
profound immunodeficiency, they need to be housed in a pro-
tected pathogen-free environment. Moreover, they have an inher-
ent tendency toward spontaneous lymphomas. Third, engraftment
of human T cells (from BM transplant or immunotherapy exper-
iments) results in high rate of lethal xenogeneic graft versus host
disease (Xeno-GVHD).
Recently, inactivation of CD47 on a C57BL/6 mouse with Rag2
and Gamma-chain knockout (triple-knockout) allowed tolerance
toward human hematopoietic stem cells. These triple-knockout
mice had no GVHD at 29 weeks after transplantation, compared
with one-third of NSG mice that develop GVHD at this point
(127). This model has not been introduced to leukemia challenge,
but it may be a promising avenue in the future, especially for
immunotherapy models.
Utilizing these mouse strains (summarized in Table 2) to
study leukemia require administration of leukemia cells, via intra-
venous route or direct into the marrow compartment (intratibial
or intrafemoral) (128, 129). Commercially available cell lines or
primary patient samples of ALL may be injected in xenogeneic
mice, with different engraftment rates, depending on the mouse
strain as well as the leukemia properties (discussed below).
QUESTIONS ADDRESSED IN THE XENOGENEIC MOUSE
MODEL
MICROENVIRONMENT OF ALL
The ability to engraft human leukemia in the murine BM pro-
vided an opportunity to study the leukemia niche within the
marrow,as well as its progression and extramedullary involvement.
Indeed, patient derived pre-B ALL cells that were intravenously
administered to SCID mice caused multiple organ involvement,
including hepatosplenomegaly, kidney and ovarian enlargement,
as well as lymphadenopathy (112). Focusing on the BM niche is
outside of this review’s scope, but some examples for utilizing
the xenograft models in these studies can be given. For example,
inhibition of CXCR4 in ALL samples administered to NOD-SCID
mice showed increased sensitivity of the blasts compared with nor-
mal hematopoietic stem cells, pointing out the CXCR4–CXCL12
axis as significant in ALL homing (130). Messinger et al. searched
for different adhesion molecules in ALL blasts in different organs
of xenografts transplanted with primary patient samples of pre-B
ALL. They identified VLA-4 and VLA-5 in the BM ALL blasts, but
not in the liver or spleen, suggesting loss of these integrins may be a
property of the leukemic cells prior to migration to extramedullary
organs (131). CNS leukemia was studied initially in the SCID
mouse. Eight days following IV administration of NALM-6 ALL
cell line, PCR demonstrated evidence of CNS leukemia (132). This
allowed experimental therapeutic tests of CNS leukemia.
LEUKEMIA STEM CELL
The study of leukemia stem cells or leukemia initiating cells
(LIC) utilized xenograft models as well, mainly by sorting cells
based on surface markers and assessing capability of initiating
leukemia in vivo. Initial studies focused on the hematopoietic
stem cell markers CD34 and CD133, as well as lineage specific
markers (CD10, CD19, CD22, CD38 for B cells, CD3 and CD7
for T cells). Cox et al. sorted patient derived T ALL cells. They
found that CD34+/CD4− or CD34+/CD7− cells were capable of
engraftment in NOD-SCID mice, with self-renewal and poten-
tial for secondary and tertiary engraftments, marking these as LIC
(121). CD34+/CD7− cells had a higher engraftment rate in NSG
mice compared with NOD/SCID mice (123), both resulting in
engraftment, differentiation with similar immunophenotype to
the original patient sample. In B-precursor ALL, CD34+CD19−
and CD34+CD10− cells sorted from patients had long-term
proliferation in NOD/SCID as well as NSG mice, compared with
CD34+CD19+ cells, suggesting the prior sub-population to be
LIC (123, 133). In contrary, other investigators have shown that
CD34+CD19+CD38± cells sorted from patients’ BM were able
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Table 2 | Xenograft mouse strains used in human leukemia research.
Strain Mutation Immune phenotype Engraftment of human
hematopoietic cells
Additional significant
limitations
Reference
T B NK Innate
Nude athymic − + + + − No IV engraftment (106–108)
SCID Prkdcscid − − + + + RS (112, 113)
SCID-Bg Prkdcscid Lyst − − Low ± + RS, leak (116)
NOD-SCID Prkdcscid NOD/Lt − − Low ± ++ RS, Th, leak (119, 122)
NOD-SCID-gamma
(NSG)
Prkdcscid NOD/Lt;
Il2rgtm1Wjl
− − − − +++ (123, 125)
NOD-truncated-gamma
(NOG)
Prkdcscid NOD/Shi;
IL2rg−/− (truncated)
− − − − ++ (159)
RS, radiosensitivity; Th, tendency for thymic lymphomas; leak, leakiness phenomena of delayed reconstitution of some immune cells.
to initiate leukemia in NSG mice, had self-renewal properties,
and resulted in lethal CD19+ leukemia in the host. Transplan-
tation of patient derived CD34+CD38−CD10−CD19− cells did
not result in overt disease, suggesting the CD34+CD19+CD38±
as the LIC (134). When sorting primary patient samples on CD133,
CD133+/CD19− as well as CD133+/CD38− cells engrafted at
low inoculating doses (5.4–6.5× 103 cells), while CD34+CD19+
cells needed an almost 100-fold higher dose to engraft. Also,
CD133+/CD19− cells were resistant to vincristine and dexam-
ethasone, suggesting this phenotype as chemo-resistant leukemia
stem cells (135). Even more controversy was introduced when, via
intrafemoral injections of purely sorted leukemia cells, le Viseur
et al. showed that different populations of the leukemia have
potential to re-establish leukemia in subsequent transplantations
to NOD/SCID mice (128).
Studies of identical twins with leukemia suggested similar LIC
with either TEL-AML1 or BCL-ABL translocations (136, 137). To
study whether the fusion proteins resulting from these translo-
cations may generate a self-renewing pre-leukemic clone, human
cord blood cells transduced with TEL/AML1 were transplanted
into NOD/SCID mice, resulting in CD34+CD38−/lowCD19+ pop-
ulation, similar to pre-leukemic phase seen in identical twins of
the patients (129).
MARKER FOR AGGRESSIVENESS/PROGNOSIS
Given the diverse nature of pediatric leukemia, a search for prog-
nostic factors, which, at diagnosis, would allow a tailored therapy
with escalation or de-escalation of treatment, is an ongoing mis-
sion. Several investigators attempted to use xenograft models to
answer this question, by injecting primary leukemic cells or BM
from leukemia patients into these mice.
Initial studies in SCID mice showed some correlation with pro-
longed remissions in patients whose cells did not engraft (111,
138, 139), but this was not consistent, nor was it consistently
observed in the NOD-SCID mouse (120, 140). In a large cohort
of patient derived pre-B ALL, only samples from low-risk patients
showed correlation between engraftment rate (time to leukemia,
TTL) in NOD-SCID mice and duration of remission (140, 141).
Similar observations were made in the NSG mouse, with lower
engraftment rate from patients who did not relapse (126). When
assessing samples from relapsed patients, these tended to grow at a
faster rate compared with samples from diagnosis when engrafted
in SCID mice (111). The TTL or rate of engraftment of the relapsed
sample in the NOD-SCID mouse correlated with remission dura-
tion (120). In vivo sensitivity to drugs, as assessed by survival of
leukemia bearing mice following drug administration vs. saline,
was also tested as a prognostic marker. Sensitivity to vincristine
and dexamethasone, but not methotrexate, correlated with remis-
sion rate of patient derived ALL engrafted in NOD-SCID mice
(120, 122). In general, these studies suggest that rate of engraft-
ment in xenogeneic models may be used as a prognostic factor,
but this method is complicated, expensive, and too difficult to be
utilized in many centers.
THERAPEUTIC APPROACHES
Most of the chemotherapy drugs used in treating pediatric ALL
were developed prior to these in vivo models. However, in the past
two decades, several novel therapies have utilized the xenograft
model as an essential part of the pre-clinical evaluation. In an
in vitro drug test, the target cells are continuously exposed to the
tested compound. An in vivo model required scheduled doses,
which have different pharmacodynamic and pharmacokinetic
properties, similar to clinical administration of drugs (142). Treat-
ment models use survival, or bioluminescence readings, as mea-
sures to evaluate in vivo treatment efficacy. This review is focused
on the modeling system and will not comprehensively address all
treatment approaches. Thus, we will discuss only selected ther-
apies tested in the xenogeneic models, including chemotherapy,
biologic agents, and immunotherapy.
New chemotherapy agents, as topotecan, have been evalu-
ated in the SCID mouse. SCID mice had a long-term remission
following topotecan administration. Also, the pharmacokinetics
of topotecan in mice was similar to the pharmacokinetics in
patients (143). mTOR inhibitors are also increasingly used in
different pediatric tumors. Mouse models of ALL demonstrated
that the mTOR inhibitor sirolimus was able to prolong sur-
vival of mice bearing ALL (144). Temsirolimus, another mTOR
inhibitor, significantly prolonged survival of NOD-SCID mice
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injected with patient derived ALL and was found to be synergistic
with methotrexate (145).
As previously mentioned, leukemic blasts require CXCR4
to stay in their BM niche. CXCR4 antagonists (Plerixafor or
AMD11070), used for hematopoietic stem cell mobilization,
were found to increase the proportion of actively cycling ALL
cells in the peripheral blood of NOD-SCID mice, prolong sur-
vival of NSG mice, and increase either strain’s sensitivity to
vincristine (130, 146).
Histone DeAcetylase (HDAC) inhibitors are also novel can-
cer medications. Balb/c-Rag−/−gammaC−/−mice bearing patient
derived T or B ALL were treated with LBH589, a HDAC inhibitor.
This treatment resulted in prolonged survival of the mice com-
pared with standard vincristine and dexamethasone treated mice,
while combination of all three therapies prolonged survival even
further (147). Other novel therapies based on specific leukemia
biology, such as CBP/catenin inhibitor (ICG-001) (148), inter-
leukin 27 administration (149), spleen-tyrosine kinase (SYK)
inhibitors (150), anti-connective tissue growth factor (CTGF)
monoclonal antibody (151) for pre-B ALL, and anti-Notch1 mon-
oclonal antibodies or for T ALL (152), were all shown to prolong
survival and/or reduce engraftment in NOD-SCID or NSG mice,
with or without additional chemotherapy.
Ricin-conjugated immunotoxin were tested in SCID mice and
shown to induce a prolonged remission compared with con-
trols (114). Messinger et al. combined an anti CD19 immuno-
toxin conjugated to poke-weed antiviral protein with several
chemotherapeutic agents, and showed that only combination
with cytarabine led to prolonged survival in SCID mice (153).
More recently, a combination of two ricin-conjugated monoclonal
antibodies (against CD19 and CD22) was shown to be effec-
tive in combination with cytarabine against ALL-bearing NSG
mice (154).
Use of adoptive-T cell based immunotherapy is an increas-
ing focus of basic as well as clinical research. As these are cell-
based therapies that proliferate in vivo, xenograft models were
an essential part of describing these therapies, and of the pre-
clinical evaluation. Cytotoxic T lymphocytes (CTLs) designed to
target specific leukemia cells, resulted in remission of NOD/SCID
mice bearing ALL (155). There is a growing interest in geneti-
cally engineered chimeric-antigen-receptor (CAR) T cells. Ability
to track leukemic progression with luciferase-transduced leukemia
cell lines was used to assess in vivo activity of CAR-T cells. A CD19-
CAR administered to NOD/SCID mice inoculated with Daudi
cells (156), and to SCID-Beige mice inoculated with NALM-6 cells
(116), resulted in disease remission, as did a CD22 CAR in NSG
mice inoculated with NALM-6 cells (157). These models can be
used to assess treatment efficacy and treatment failures (escape
mechanisms) on ALL cell lines as well as primary samples, and
were able to identify the periodontal region as a new sanctuary
site of leukemia, in which homing of the CAR-T cells was inade-
quate (116). Some major disadvantages of these models can also
be elucidated when testing cell-based therapies: lack of a native
immune system limits true studies of engraftment and persistence
of adoptively transferred cells, in an environment without com-
petition and/or native cytokine support. Also, there is an inherent
limited survival of human T cells on some models (SCID-Beige
mice) (116) and graft versus host disease frequently arises from
the adoptively transferred human T cells against the mouse (158).
SUMMARY
As described in this review, there are multiple murine mod-
els in current ALL research. The xenogeneic model, especially
the NOD-SCID and NSG strains, has superb ability to engraft
human hematopoietic cells and human leukemia, and may serve
as an appropriate platform for in vivo research of human-derived
leukemia, utilizing either cell lines or patient derived cells. Given
the diverse landscape of acute leukemia as far as genetic abnormal-
ities, the ability to engraft patient derived cells is a major advantage
of xenogeneic models. Also, they may serve as in vivo platforms
for drug testing against ALL. Moreover, the relative simplicity of
using bioluminescent imaging of leukemia (cell lines or patient
samples) in xenogeneic mice for evaluation of disease has pro-
vided a method to detect proliferation and progression of disease
without sacrificing multiple mice (144). Though bioluminescent
imaging has been used in syngeneic models of other cancers, it has
not been successfully utilized in leukemia.
Major limitations of these models include limited life span and
even more – lack of a native immune system, which is crucial to
this model’s engraftment properties. The immune system’s role in
the biology of leukemia development and ALL niche cannot be
assessed in these models. Also, novel therapies, as immunomod-
ulatory drugs or bispecific T cell engagers (BiTE) antibodies, are
based on the immune system and cannot be completely assessed
in this model.
The syngeneic model allows the study of leukemia in an
immunocompetent host. This model can be used extensively
to study the leukemia microenvironment in different organs.
Though these models are driven by common human ALL genetic
rearrangements or oncogene overexpression, in mice (as in
humans) these translocations are not sufficient for leukemogene-
sis. Thus, these mice have additional germline alterations, which
may not represent the additional hits in human disease. Also, these
are limited models that cannot match the full spectrum of human
acute leukemias. Moreover, given that these leukemia models are of
murine origin, many drugs developed for human leukemia cannot
be tested given the species barrier.
In summary, murine models play an essential part of leukemia
research as well as therapeutic development. The benefits and
limitations of each model should be weighed when addressing a
specific study question. Altogether, the development of both xeno-
geneic as well as syngeneic models create many opportunities to
answer fundamental questions of leukemia biology, and serves as
a platform for the development of novel therapies.
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